BIRK · Birkenstock Holding plc

Current Thesis

Birkenstock Holding plc’s remaining recovery case is that its raised earnings outlook can support a weekly reclaim of $36 before a weekly close below $31 ends the case. Those are the research thresholds carried in the September 5 coverage; the September 11, 2026 adjusted close of $31.13 leaves the lower boundary unresolved. This is a low-conviction inference from operating growth against falling prices, rather than evidence that a recovery has begun.

The narrative is dead — the previously identified $36 boundary remains broken at the September 11 close, despite the August 13 guidance increase. BMO initiated coverage on September 9 with Market Perform and a $35 analyst target, adding a more restrained valuation assessment to the record. An initiation is not a downgrade by an existing analyst. BMO coverage report

Bullish and bearish views on Birkenstock Holding plc

The model's bull view on Birkenstock Holding plc (BIRK), in brief: Direct demand continued growing. For the quarter ended June 30, 2026, Birkenstock reported revenue of €720 million, up 13% reported and 15% excluding currency movements; direct-to-consumer revenue grew 16% excluding currency movements. These August 13 results support the… The bear view: Price deterioration remains measured. The September 11, 2026 adjusted series records a three-month decline of 36.1%, with the $31.13 close 36.4% below the trailing annual high of $48.97. These observations do not establish how much further prices might fall. Sponsor supply is… Both cases follow in full.

Bull Case

• Direct demand continued growing. For the quarter ended June 30, 2026, Birkenstock reported revenue of €720 million, up 13% reported and 15% excluding currency movements; direct-to-consumer revenue grew 16% excluding currency movements. These August 13 results support the operating component of the recovery case. Company results
• Management raised the earnings hurdle. On August 13, 2026, management raised full-year constant-currency revenue growth guidance to 15% and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to at least €710 million. Full-year results below either threshold would break that operating premise. Company results
• The redemption was completed. The August 17, 2026 Form 6-K summary reports completion of the redemption of 12,761,613 company shares for cancellation. This establishes an actual capital transaction; it does not establish continuing market demand. Filing summary

Bear Case

• Price deterioration remains measured. The September 11, 2026 adjusted series records a three-month decline of 36.1%, with the $31.13 close 36.4% below the trailing annual high of $48.97. These observations do not establish how much further prices might fall.
• Sponsor supply is therefore an observed event, correcting the earlier framing of it solely as a prospective risk. Filing summary
• Margins absorbed tariff costs. The August 13, 2026 release reported June-quarter adjusted gross margin of 59.2%, versus 60.5% a year earlier, including 70 basis points of tariff pressure. Full-year adjusted EBITDA margin below management’s 30.2–30.5% guidance would invalidate the margin-resilience premise. Company results

Setup & Price Structure

The September 11, 2026 close of $31.13 is above the published $31 weekly invalidation threshold. The 14-day relative strength index (RSI) is 22.7 in the same adjusted series. That measures weak recent momentum; no reversal-frequency sample accompanies it, so it cannot support a probability claim about an imminent bounce.

A weekly close above the previously published $36 boundary defines completion of this limited recovery case before invalidation. BMO’s September 9 target of $35 remains an analyst valuation, not an observed resistance level. No current moving-average, short-interest or fund-flow measurements are available in this record; the August offering establishes supply, but does not quantify current crowding.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Fiscal year end. This is the accounting cutoff stated in the company’s financial calendar, with no results release attached. It does not itself reveal whether the August guidance was met. Company financial calendar

As checked on September 13, 2026, the company’s events page lists no confirmed earnings release or conference within the next 30 days. The full-year results remain the operating test, but their date is unconfirmed; the prior December estimate is not a scheduled event. Company events calendar

What Would Change Our Mind

Loss of the remaining published price boundary ends the recovery case: a weekly close below $31 invalidates it. That is a research condition, not evidence that the market has established support there. The September 11 close of $31.13 has not breached it.

A weekly reclaim above $36 before that breach would resolve the limited price-recovery forecast positively. Separately, full-year constant-currency revenue growth below 15% or adjusted EBITDA below €710 million would contradict the August 13 operating premise. Failure to announce results by September 30 is not a thesis break because no announcement deadline is company-dated.

Correlation Notes

This remains a single-company recovery case. The September 11, 2026 price snapshot contains no matched sector-return series, so it supports no claim that consumer-discretionary rotation explains Birkenstock’s decline or will reverse it.

Currency exposure is observable in the August 13 release: June-quarter reported revenue growth was 13%, compared with 15% excluding currency movements. That identifies an operating translation effect; it does not establish a measured correlation between the shares and an exchange rate.